Envestnet Asset Management
ACOR

Envestnet Asset Management’s Acorda Therapeutics ACOR Stock Holding History

Envestnet Asset Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Hold
0
– -$1K – 2788
2018
Q2 		– Hold
0
– – – 2838
2018
Q1 		– Hold
0
– – – 2818
2017
Q4 		– Hold
0
– – – 2938
2017
Q3 		– Hold
0
– – – 2877
2017
Q2 		– Sell
-2
Closed -$3.96K – 3016
2017
Q1 		$6K Sell
2
-1
-33% -$2.88K ﹤0.01% 2878
2016
Q4 		$8K Sell
3
-6
-67% -$14.3K ﹤0.01% 2811
2016
Q3 		$22K Sell
9
-4
-31% -$11.9K ﹤0.01% 2802
2016
Q2 		$39K Sell
13
-1
-7% -$3.25K ﹤0.01% 2824
2016
Q1 		$46K Sell
14
-4
-22% -$16.6K ﹤0.01% 2751
2015
Q4 		$94K Sell
18
-2
-10% -$8.74K ﹤0.01% 2395
2015
Q3 		$65K Buy
+20
New +$77.6K ﹤0.01% 2536
2014
Q4 		– Sell
-2
Closed -$7K – 2758
2014
Q3 		$7K Buy
+2
New +$7.5K ﹤0.01% 2247
2014
Q1 		– Hold
0
– -$1K – 2658
2013
Q4 		– Hold
0
– – – 2385
2013
Q3 		– Hold
0
– – – 2335
2013
Q2 		– Hold
0
– – – 2266

Other funds holding ACOR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Envestnet Asset Management's ACOR Position: Q3 2018 in Review

Envestnet Asset Management held its Acorda Therapeutics (ACOR) position steady in Q3 2018 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2788.

Envestnet Asset Management first reported a position in ACOR in Q3 2014 and has held it in 8 quarters since. The position peaked at $94K in Q4 2015. 174 funds tracked by Wall St. Rank hold ACOR as of Q3 2018.

  • Envestnet Asset Management held 0 shares of Acorda Therapeutics worth $0 as of Q3 2018.
  • Envestnet Asset Management left its Acorda Therapeutics share count unchanged in Q3 2018.
  • Acorda Therapeutics made up ﹤0.01% of Envestnet Asset Management's portfolio in Q3 2018, its #2788 holding.
  • Envestnet Asset Management first reported a position in Acorda Therapeutics in Q3 2014 and has held it in 8 quarters since.
  • Envestnet Asset Management's Acorda Therapeutics position peaked at $94K in Q4 2015.
  • 174 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2018.

Based on Envestnet Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.